ReviewChildhood kidney diseases2025
How to treat recurrent focal segmental glomerulosclerosis after kidney transplantation in children.
Review in Childhood kidney diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal segmental glomerulosclerosis (FSGS), a significant cause of kidney failure in children, is a common pathological diagnosis in cases of idiopathic nephrotic syndrome, especially steroid-resistant ones. FSGS has the potential to recur after kidney transplantation, often leading to graft loss. However, not all children with FSGS experience recurrence posttransplantation, such as those with genetic or secondary forms, which have minimal risk. Moreover, advancements in management, including intensive plasmapheresis and immunosuppressive therapies like rituximab, have increased remission rates in cases of recurrence. Identifying patients at high risk of recurrence, such as those with an initial treatment response or previous failed transplantation, is crucial. These children require close monitoring of proteinuria and prompt, intensive treatment upon recurrence to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.